Abstract: The present invention relates to a strong base-initiated N-carboxyanhydride rapid ring-opening polymerisation method. Specifically, the method comprises steps of: performing a polymerisation reaction with one or more amino acid N-carboxyanhydride monomers in an organic solvent in the presence of an initiator, so as to form an amino acid polymer, wherein the initiator is selected from the following group: LiHMDS, NaHMDS, KHMDS, or a combination thereof. The method significantly increases the speed of traditional NCA polymerisation and prepares a long-chain polymer, and the prepared amino acid polymer may be used as an anti-bacterial material, an anti-tumour material, a tissue engineering scaffold or a self-assembling material.

Abstract: Disclosed are a polypeptide polymer-doped bone marrow cavity filler and the use thereof in the treatment of osteomyelitis, wherein the polypeptide polymer is used for being doped in a bone marrow cavity filler or preparing a bone marrow cavity filling antibacterial material for treating osteomyelitis, has efficient antibacterial activity on common staphylococcus aureus, etc., in osteomyelitis, is not easy to induce bacteria to generate drug resistance, has good biocompatibility in environments such as bone marrow and blood, has good stability, and still keeps activity after forming heat release and even the autoclaving of bone cement.

Abstract: The present invention relates to a strong base-initiated N-carboxyanhydride rapid ring-opening polymerisation method. Specifically, the method comprises steps of: performing a polymerisation reaction with one or more amino acid N-carboxyanhydride monomers in an organic solvent in the presence of an initiator, so as to form an amino acid polymer, wherein the initiator is selected from the following group: LiHMDS, NaHMDS, KHMDS, or a combination thereof. The method significantly increases the speed of traditional NCA polymerisation and prepares a long-chain polymer, and the prepared amino acid polymer may be used as an anti-bacterial material, an anti-tumour material, a tissue engineering scaffold or a self-assembling material.

Abstract: A method and corresponding composition to inhibit outgrowth of C. difficile spores and/or to inhibit growth of C. difficile vegetative cells in a mammal in which an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof is administered to the subject.

Abstract: A method and corresponding pharmaceutical composition for inhibiting the growth of fungi. The method uses an antifungal composition containing as the active ingredient one or more nylon-3 copolymers having a formula: or a salt thereof, wherein: each R is independently hydrogen or C1-C6-alkyl; each R1, R3, R4, R5, and R6 are each independently selected from the group consisting of hydrogen or substituted or unsubstituted C1-C6-alkyl; each R2 is C1-C6-alkylene; “A” is hydrogen or an amino-protecting group; “B” is hydroxyl or a carboxy-protecting group; and “X,” “Y,” and “Z” are positive numbers.

Abstract: A method and corresponding composition to inhibit outgrowth of C. difficile spores and/or to inhibit growth of C. difficile vegetative cells in a mammal in which an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof is administered to the subject.

Abstract: Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the line leaf inula flower lactone A shows positive therapeutic effect on EAM. Line leaf inula flower lactone A is used as the sole active ingredient and combined with a conventional pharmaceutical carrier in a drug for treating myocarditis, and the pharmaceutical composition may be in the form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.

Abstract: Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

Abstract: Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the line leaf inula flower lactone A shows positive therapeutic effect on EAM. Line leaf inula flower lactone A is used as the sole active ingredient and combined with a conventional pharmaceutical carrier in a drug for treating myocarditis, and the pharmaceutical composition may be in the form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.

Abstract: Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.